Zentalis' dual-track FDA strategy enters Phase 3 with ASPENOVA

Zentalis Pharmaceuticals has opened a confirmatory Phase 3 trial while simultaneously pursuing accelerated approval for the same compound, a regulatory sequencing decision that RA directors and CMC teams will recognise as a deliberate hedge against the FDA's post-accelerated-approval confirmation requirements.

ASPENOVA Phase 3 enrolls azenosertib vs. standard-of-care chemotherapy

The ASPENOVA trial (NCT07546500, GOG-3147, ENGOT-ov109, APGOT-OV27) dosed its first patient on 5 May 2026. The randomised, controlled study targets approximately 420 patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and compares azenosertib monotherapy against investigator's choice chemotherapy. The trial is being conducted in collaboration with The GOG Foundation, ENGOT, and APGOT, giving it a global enrollment footprint across North America, Europe, and Asia-Pacific.

Azenosertib is a first-in-class oral WEE1 inhibitor dosed at 400 mg once daily on a 5-days-on, 2-days-off schedule, the regimen selected following a DENALI Part 2a interim analysis reported in April 2026, which showed a differentiated response rate over the 300 mg cohort with comparable safety. Both ASPENOVA and the registration-intended DENALI Phase 2 trial use this dose.

The regulatory read for RA directors benchmarking dual-track programs

Zentalis is executing a structure that regulatory affairs leads will find instructive: DENALI Part 2 is positioned to generate the response-rate data needed for an accelerated approval submission, with a topline readout expected by year-end 2026, while ASPENOVA runs concurrently as the confirmatory study required for conversion to full approval under FDA's framework. This architecture directly addresses the agency's tightened expectations around confirmatory trial readiness, a pressure point that has become more acute since the Omnibus appropriations provisions of 2023 gave FDA expanded authority to withdraw accelerated approvals when confirmatory trials stall.

For RA and clinical operations teams, the practical implication is sequencing: ASPENOVA's enrollment must progress at a pace that keeps the confirmatory timeline credible to regulators at the time of any accelerated approval decision. Enrollment lag in the confirmatory arm has been a documented vulnerability in prior oncology programs.

What to track ahead of the DENALI year-end readout

The immediate checkpoint is the DENALI Part 2 topline data, expected by end of 2026. That readout will determine whether Zentalis files for accelerated approval and, if so, the timeline pressure it places on ASPENOVA's enrollment curve. RA directors monitoring the program should also watch for FDA feedback on the accelerated approval pathway, which Zentalis has flagged as pending.

ASPENOVA's multi-group structure, spanning GOG-F, ENGOT, and APGOT, distributes site activation risk globally, but also introduces ICH E6(R3) compliance obligations across multiple regulatory jurisdictions simultaneously.

The DENALI topline readout by year-end 2026 will set the pace for any accelerated approval filing and, in turn, define the enrollment urgency Zentalis and its trial network must sustain in ASPENOVA.